BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.
The company is a separate entity from Merck & Co., which is based in the U.S.
Ruling In "Assault Weapons" Case Could Gut Gun Control Nationwide
Winners and Losers from Tonight's ABC Debate | RedState
Yahoo editor 'pretty sure' Rubio wrong about Roe v. Wade
Girls Go Wild Over Casual Sex | Human Events
A Dividend ETF That Could Help Recover Your Losses
Analysis: Governors Soar, Rubio Stumbles Early On in Crucial New Hampshire Debate
Open thread: Brace for impact. The New Hampshire GOP debate